Differential effects of procaspase-3 activating compounds in the induction of cancer cell death

Area of Science:

• Oncology
• Molecular Biology
• Pharmacology

Background:

• Apoptosis evasion is a hallmark of cancer, making apoptosis induction a promising therapeutic strategy.
• Procaspase-activating compounds (PACs) like PAC-1 and S-PAC-1 chelate zinc ions to restore procaspase-3 activity, inducing cancer cell death.
• While PAC-1 exhibits transient neurotoxicity at high doses, S-PAC-1 is well-tolerated and has undergone clinical evaluation.

Purpose of the Study:

• To investigate the distinct mechanisms of cell death induced by PAC-1 and S-PAC-1 at varying concentrations.
• To explore the potential of PAC-1 and S-PAC-1 in personalized anticancer therapy.
• To inform clinical development strategies for these compounds.

Main Methods:

• In vitro and in vivo studies using PAC-1 and S-PAC-1.
• Analysis of gene expression profiles, cellular and mitochondrial morphology.
• Intracellular calcium (Ca2+) concentration measurements.
• Assessment of endoplasmic reticulum (ER) stress markers.

Main Results:

• At low concentrations (<50 μM), PAC-1 and S-PAC-1 induce cell death via similar mechanisms.
• High concentrations of PAC-1 induce unique cell death features, including ER stress, altered gene expression, and morphological changes.
• S-PAC-1 demonstrates safety at high doses, supporting its clinical evaluation.

Conclusions:

• PAC-1 and S-PAC-1 exhibit concentration-dependent differences in their mechanisms of cancer cell death induction.
• High-dose PAC-1's ER stress-mediated apoptosis suggests specific dosing strategies (bolus).
• S-PAC-1's safety profile supports continuous infusion strategies for clinical development.